Literature DB >> 28271718

Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city.

Sarah M Peitzmeier1, Catherine Tomko2, Erin Wingo1, Anne Sawyer3, Susan G Sherman4,5,6, Nancy Glass5, Chris Beyrer4,6, Michele R Decker1,4,5.   

Abstract

Biomedical HIV prevention tools including oral pre-exposure prophylaxis (PrEP) and vaginal microbicidal rings hold unique value for high-risk women who may have limited capacity for condom negotiation, including the key populations of sex workers and drug users. Commercial sex is a PrEP indicator in CDC guidelines, yet little is known about female sex workers' (FSWs) knowledge of and attitudes toward PrEP or the recently developed monthly vaginal microbicide rings. We describe knowledge and attitudes toward PrEP and microbicide rings in a sample of 60 mostly drug-using FSWs in Baltimore, Maryland, a high HIV-prevalence US city. Just 33% had heard of PrEP, but 65% were interested in taking daily oral PrEP and 76% were interested in a microbicide vaginal ring; 87% were interested in at least one of the two methods. Results suggest method mix will be important as biomedical tools for HIV prophylaxis are implemented and scaled up in this population, as 12% were interested in PrEP but not vaginal rings, while 19% were interested in vaginal rings but not in PrEP. Self-efficacy for daily oral adherence was high (79%) and 78% were interested in using PrEP even if condoms were still necessary. Women who had experienced recent client-perpetrated violence were significantly more interested in PrEP (86% vs 53%, p = 0.009) and microbicidal rings (91% vs 65%, p = 0.028) than women who had not recently experienced violence. No differences were observed by demographics nor HIV risk behaviors, suggesting broad potential interest in daily PrEP and monthly-use vaginal microbicides in this high-risk population.

Entities:  

Keywords:  Sex workers; microbicides; people who inject drugs; pre-exposure prophylaxis; vaginal rings; violence

Mesh:

Substances:

Year:  2017        PMID: 28271718      PMCID: PMC5591065          DOI: 10.1080/09540121.2017.1300628

Source DB:  PubMed          Journal:  AIDS Care        ISSN: 0954-0121


  18 in total

1.  Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Authors:  Jared M Baeten; Thesla Palanee-Phillips; Elizabeth R Brown; Katie Schwartz; Lydia E Soto-Torres; Vaneshree Govender; Nyaradzo M Mgodi; Flavia Matovu Kiweewa; Gonasagrie Nair; Felix Mhlanga; Samantha Siva; Linda-Gail Bekker; Nitesha Jeenarain; Zakir Gaffoor; Francis Martinson; Bonus Makanani; Arendevi Pather; Logashvari Naidoo; Marla Husnik; Barbra A Richardson; Urvi M Parikh; John W Mellors; Mark A Marzinke; Craig W Hendrix; Ariane van der Straten; Gita Ramjee; Zvavahera M Chirenje; Clemensia Nakabiito; Taha E Taha; Judith Jones; Ashley Mayo; Rachel Scheckter; Jennifer Berthiaume; Edward Livant; Cindy Jacobson; Patrick Ndase; Rhonda White; Karen Patterson; Donna Germuga; Beth Galaska; Katherine Bunge; Devika Singh; Daniel W Szydlo; Elizabeth T Montgomery; Barbara S Mensch; Kristine Torjesen; Cynthia I Grossman; Nahida Chakhtoura; Annalene Nel; Zeda Rosenberg; Ian McGowan; Sharon Hillier
Journal:  N Engl J Med       Date:  2016-02-22       Impact factor: 91.245

2.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.

Authors:  Michael C Thigpen; Poloko M Kebaabetswe; Lynn A Paxton; Dawn K Smith; Charles E Rose; Tebogo M Segolodi; Faith L Henderson; Sonal R Pathak; Fatma A Soud; Kata L Chillag; Rodreck Mutanhaurwa; Lovemore Ian Chirwa; Michael Kasonde; Daniel Abebe; Evans Buliva; Roman J Gvetadze; Sandra Johnson; Thom Sukalac; Vasavi T Thomas; Clyde Hart; Jeffrey A Johnson; C Kevin Malotte; Craig W Hendrix; John T Brooks
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

3.  Tenofovir-based preexposure prophylaxis for HIV infection among African women.

Authors:  Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje
Journal:  N Engl J Med       Date:  2015-02-05       Impact factor: 91.245

4.  Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Kachit Choopanya; Michael Martin; Pravan Suntharasamai; Udomsak Sangkum; Philip A Mock; Manoj Leethochawalit; Sithisat Chiamwongpaet; Praphan Kitisin; Pitinan Natrujirote; Somyot Kittimunkong; Rutt Chuachoowong; Roman J Gvetadze; Janet M McNicholl; Lynn A Paxton; Marcel E Curlin; Craig W Hendrix; Suphak Vanichseni
Journal:  Lancet       Date:  2013-06-13       Impact factor: 79.321

5.  High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya.

Authors:  Elisabeth Maria Van der Elst; Judie Mbogua; Don Operario; Gaudensia Mutua; Caroline Kuo; Peter Mugo; Jennifer Kanungi; Sagri Singh; Jessica Haberer; Frances Priddy; Eduard Joachim Sanders
Journal:  AIDS Behav       Date:  2013-07

6.  Preexposure prophylaxis for HIV infection among African women.

Authors:  Lut Van Damme; Amy Corneli; Khatija Ahmed; Kawango Agot; Johan Lombaard; Saidi Kapiga; Mookho Malahleha; Fredrick Owino; Rachel Manongi; Jacob Onyango; Lucky Temu; Modie Constance Monedi; Paul Mak'Oketch; Mankalimeng Makanda; Ilse Reblin; Shumani Elsie Makatu; Lisa Saylor; Haddie Kiernan; Stella Kirkendale; Christina Wong; Robert Grant; Angela Kashuba; Kavita Nanda; Justin Mandala; Katrien Fransen; Jennifer Deese; Tania Crucitti; Timothy D Mastro; Douglas Taylor
Journal:  N Engl J Med       Date:  2012-07-11       Impact factor: 91.245

7.  Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study.

Authors:  Andreas B Eisingerich; Ana Wheelock; Gabriela B Gomez; Geoffrey P Garnett; Mark R Dybul; Peter K Piot
Journal:  PLoS One       Date:  2012-01-11       Impact factor: 3.240

8.  HIV due to female sex work: regional and global estimates.

Authors:  Annette Prüss-Ustün; Jennyfer Wolf; Tim Driscoll; Louisa Degenhardt; Maria Neira; Jesus Maria Garcia Calleja
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

9.  HIV pre-exposure prophylaxis interest among female sex workers in Guangxi, China.

Authors:  Li Ye; Suosu Wei; Yunfeng Zou; Xiaobo Yang; Abu S Abdullah; Xiaoni Zhong; Yuhua Ruan; Xinqin Lin; Mingqiang Li; Deren Wu; Junjun Jiang; Peiyan Xie; Jiegang Huang; Bingyu Liang; Bo Zhou; Jinming Su; Hao Liang; Ailong Huang
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

10.  HIV infection among heterosexuals at increased risk--United States, 2010.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2013-03-15       Impact factor: 17.586

View more
  22 in total

1.  Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis.

Authors:  Chen Zhang; James McMahon; Janie Simmons; L Lauren Brown; Robertson Nash; Yu Liu
Journal:  AIDS Behav       Date:  2019-10

Review 2.  Designing and developing suppository formulations for anti-HIV drug delivery.

Authors:  Anthony S Ham; Robert W Buckheit
Journal:  Ther Deliv       Date:  2017-08

3.  Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States.

Authors:  D Kerrigan; A Mantsios; R Grant; M Markowitz; P Defechereux; M La Mar; S W Beckham; P Hammond; D Margolis; M Murray
Journal:  AIDS Behav       Date:  2018-11

4.  Awareness and Interest in HIV Pre-Exposure Prophylaxis Among Street-Based Female Sex Workers: Results from a US Context.

Authors:  Catherine Tomko; Ju Nyeong Park; Sean T Allen; Jennifer Glick; Noya Galai; Michele R Decker; Katherine H A Footer; Susan G Sherman
Journal:  AIDS Patient Care STDS       Date:  2019-01-11       Impact factor: 5.078

5.  The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review.

Authors:  Jennifer L Glick; Rienna Russo; Belinda Jivapong; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman
Journal:  AIDS Behav       Date:  2020-05

6.  Oral and vaginal HIV pre-exposure prophylaxis product attribute preferences among female sex workers in the Mexico-US border region.

Authors:  H A Pines; S A Strathdee; C W Hendrix; C C Bristow; A Harvey-Vera; C Magis-Rodríguez; G Martinez; S J Semple; T L Patterson
Journal:  Int J STD AIDS       Date:  2018-08-31       Impact factor: 1.359

Review 7.  The global response and unmet actions for HIV and sex workers.

Authors:  Kate Shannon; Anna-Louise Crago; Stefan D Baral; Linda-Gail Bekker; Deanna Kerrigan; Michele R Decker; Tonia Poteat; Andrea L Wirtz; Brian Weir; Marie-Claude Boily; Jenny Butler; Steffanie A Strathdee; Chris Beyrer
Journal:  Lancet       Date:  2018-07-20       Impact factor: 79.321

8.  HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system.

Authors:  Ronnye Rutledge; Lynn Madden; Onyema Ogbuagu; Jaimie P Meyer
Journal:  AIDS Care       Date:  2018-03-11

9.  The PEARL study: a prospective two-group pilot PrEP promotion intervention for cisgender female sex workers living in Baltimore, MD, U.S.

Authors:  D Pelaez; N P Weicker; J Glick; J V Mesenburg; A Wilson; H Kirkpatrick; E Clouse; S G Sherman
Journal:  AIDS Care       Date:  2021-02-24

10.  Oral Pre-Exposure Prophylaxis (PrEP) for HIV Prevention in Adolescents and Young Adults.

Authors:  Tanya L Kowalczyk Mullins; Corinne E Lehmann
Journal:  Curr Pediatr Rep       Date:  2018-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.